Abstract We determined the in vivo role of stromalinteracting molecule 1 (STIM1) in the regulation of vascular function using endothelial cell (EC)-and smooth-muscle (SM)-specific knockout mice. Systolic blood pressure and glucose levels were similar in all mice (Stim1 SMC−/− , Stim1
Introduction
Vascular function is an important mechanism that regulates local blood flow and maintains normal functions of organs and tissue [16] . It is well established that cardiovascular diseases are associated with vascular endothelial and smooth muscle cell dysfunctions [2, 11] . The Ca 2+ is a universal second messenger that regulates vascular function [11, 18] Stromal-interacting molecule 1 (STIM1) has recently been identified as a central molecular component of storeoperated Ca 2+ entry (SOCE) in both endothelial cells and smooth muscle [1, 17, 23] . SOCE is mediated by the highly Ca 2+ selective, Ca 2+ release-activated Ca 2+ (CRAC) current which allows Ca 2+ influx across the plasma membrane upon the emptying of endoplasmic reticulum (ER) Ca 2+ stores. STIM1 is the long-sought ER Ca 2+ sensor that senses ER Ca 2+ store depletion to activate Orai1, the store-operated Ca 2+ channel located at the plasma membrane [11] . STIM1 expression is increased in vessels in hypertension and during neointima formation in animals [23, 9] and preventing STIM1 upregulation inhibits neointima formation [23, 10, 3] . STIM1 was shown to be required for endothelial permeability in response to thrombin and bacterial lipopolysaccharides [8, 19] . Estrada et al. reported decreased STIM1 protein expression and disrupted Ca 2+ homeostasis in coronary endothelial cells from a mouse model of streptozotocin-induced hyperglycemia associated with severe weight loss and sickness [7] . However, the role of STIM1 in endothelial cells vs. smooth muscle cells in the basic mechanisms of microvascular homeostasis and reactivity has not been documented. Our results provide the first evidence that depending on the cell type considered, either vascular smooth muscle or endothelial cells, STIM1 plays a distinct role in the regulation of microvascular function highlighting the need to distinguish between endothelial and smooth muscle STIM1 in studies using animal models of vascular diseases.
Results and discussion
The specific knockout of STIM1 in smooth muscle cells (SMC) was accomplished using the SM22α-CreKI + mouse that provides strong Cre expression in smooth muscle [22] , which leads to a specific and complete deletion of EC−/− mice in the mesenteric resistance arteries (MRA) and the heart. Additionally, western blot on lysates from mesenteric resistance arteries indicates a reduction in STIM1 expression in Stim1 SMC−/− (Fig. 1b ). Blood glucose levels are similar in all groups of mice tested ( Table 1) . The heart weight/tibia length ratio was significantly low in Stim1 SMC−/− and Stim1 EC−/− compared to control and heterozygous mice (Table 1) . These results indicate that Stim1 SMC−/− and Stim1 EC−/− have a small heart and could affect the physiopathology in a stress challenge conditions. The mechanism is still unclear. However, it has been reported that in vitro deletion of STIM1 in rat's cardiomyocytes reduced growth factors levels [20] . Thus, it is likely that STIM1 regulates growth factors release that could dictate the heart weight. The systolic blood pressure is in the range of normotensive and is similar in all groups (Table 1) indicating that the absence of STIM1 in vascular endothelial cells or smooth muscle cells does not, on its own, cause hypertension, hypotension, hyperglycemia, or hypoglycemia. STIM1 expression was enhanced in platelets from type 2 diabetic patients [21] . However, it has been shown that in mice infused with streptozotocin (STZ), a diabetic model known for causing severe sickness and weight loss, STIM1 expression was downregulated and associated with vascular dysfunction [7] . We previously reported microvascular endothelial and smooth muscle cell dysfunction in type 2 diabetic mice [4, 12, 5] . It is highly likely that the enhanced STIM1 expression in type 2 diabetes and hypertension could be causally involved in the impairment of arterial function. However, this has yet to be firmly demonstrated using a genetic approach.
The body weight was significantly reduced in Stim1 SMC−/− and Stim1 EC−/− compared to that of the controls and heterozygous (Table 1) . These results indicate the potential contribution of STIM1 in the control of the body weight. These data are supported by previous studies indicating a reduction in body weight in Stim1 SMC−/− mice [14] .
Microvascular smooth muscle cell, in vivo, responds to a variety of vasoconstrictors to maintain vascular tone. Thus, the vasoconstriction response to potassium chloride and thromboxane analogue (U46619) was similar in all groups of mice tested (Figs. 1c, d and 3a, b) . However, the vasoconstriction in response to phenylephrine, a sympathetic stimulator, was drastically reduced in resistance and conductance arteries in Stim1 SMC−/− mice only (Figs. 1e and 3c ). This is likely caused by alteration of intracellular signaling in response to phenylephrine. STIM1 is likely an essential component of α-adrenoreceptor signaling in smooth muscle but it is not involved in thromboxane-mediated contractility. Our results are supported by previous studies showing that vasoconstriction in response to urotensin II, which binds to a Gqprotein coupled receptor, was significantly reduced when STIM1 was downregulated [6] . Similarly, the Gill group also found a reduction in vasoconstriction in response to phenylephrine in Stim1 SMC−/− mice, albeit of smaller amplitude compared to our results [15] . The reduction in vasoconstriction in response to phenylephrine is independent of blood pressure since arterial blood pressure is similar in all groups indicating the specific role of STIM1 in sympathetic activity. The contraction in response to phenylephrine was not altered in mice lacking STIM1 in EC indicating that STIM1 in SMC specifically regulates vasoconstriction induced by sympathetic stimulation. STIM1 knockdown or knockout in essentially all cell type studied so far has been associated with inhibited agonist-mediated Ca 2+ influx to a large number of membrane receptors, including alpha1 receptor-mediated Ca 2+ influx specifically in smooth muscle, as recently reported [6] .
The arterial tone is mainly regulated by the contraction of SMC dictated by intrinsic mechanisms and factors released by endothelial cells. The endothelium-dependent relaxation was not affected in Stim1 SMC−/− and Stim1 SMC−/+ (Figs. 1f and 3d). However the endothelium-dependent relaxation was significantly reduced in Stim1 EC−/+ and drastically inhibited in 
Stim1
EC−/− (Figs. 1f and 3d) . Our results indicate the differential effect of STIM1 in the regulation of microvascular reactivity (Fig. 2) . The deletion of STIM1 in either ECs or SMCs did not affect the sensitivity of SMCs to nitric oxide since the relaxation to a nitric oxide donor is similar in all groups of mice (Figs. 1g and 3d) . Nitric oxide markers (nitrite and cGMP) levels were significantly reduced while NADPH oxidase activity was augmented in Stim1 EC−/− compared to the other groups of mice (Figs. 1h, i, j and 3f, g, h) . These results indicate that STIM1 in ECs regulates eNOS-and oxidative stress-dependent pathways likely through control of NADPH oxidase activity, consistent with earlier reports [8] . Our results showed a slight increase in the systolic blood pressure that is similar between heterozygous Stim1 EC−/+ and homozygous Stim1 EC−/− mice. While the endothelium function was slightly but significantly reduced in the heterozygous group, it was severely reduced in the homozygous group. Therefore, the same slight increase in systolic blood pressure is unlikely to explain the differential effect on endothelial function between the two groups of mice (Fig. 4) . To rule out potential adaptive responses related to the chronic downregulation of STIM1, we acutely downregulated STIM1 in vitro in endothelial and smooth muscle cells in resistance arteries using molecular knockdown (Fig. 1k) . Our results indicate a reduced phenylephrine-induced contraction, while the response to thromboxane was not affected (Fig. 1l, m) emphasizing the selective role of STIM1 in sympathetic vasoconstriction. These results are consistent with data in Stim1 SMC−/− mice, ruling out any adaptive responses in vessels from knockout mice. Additionally, the in vitro acute ) and subsequent Ca 2+ entry (upon addition of 2 mM Ca 2+ to the bath solution) in ECs stimulated with 10 μM histamine. ECs were transfected with either nontargeting siRNA (siNT) or STIM1 siRNA (a). The SOCE inhibitor, BTP2 at 10 μM was added when the Ca 2+ entry phase in ECs was maximal (grey arrows) followed by ionomycin (10 μM; black arrows); the latter is a Fura2 loading control. Traces shown represent an average from several ECs (see color-coded N for each trace). b Statistical summary on extent of Ca 2+ entry in ECs stimulated with histamine (N=71 and 98 for siNT and siSTIM1, respectively) taken from five independent experiments, including experiments described in a. c, d, representative Ca 2+ imaging traces similar to those shown in a, but representing average Fura2 ratios from several ECs stimulated with either 100 nM thrombin (c) or 2 μM thapsigargin (d). ***p<0.001 downregulation of STIM1, reduced microvascular endotheliumdependent relaxation (Fig. 1n) . Furthermore, NADPH oxidase activity was increased after acute down regulation of STIM1 (Fig. 1o) . To strengthen our data, we used laser capture microdissection to isolate EC and SMC from the aorta from all group of mice. Our data indicates an increase in NADPH oxidase activity in EC and no difference was reported in SMC (Fig. 5b, c) . We also show that two vasoactive compounds known to produce NO, histamine and thrombin, activate Ca 2+ entry in vascular endothelial cells (ECs) through a pathway pharmacologically reminiscent of store-operated Ca 2+ entry (SOCE), namely inhibition by the pyrazole BTP2 (10 μM; Fig. 2 ), 2-Aminoethoxydiphenyl borate (2-APB 25 μM, Fig. 4 ) and low concentrations of gadolinium (Gd 3+ , 5 μM, Fig. 4.) ; thapsigargin is used throughout as a control (Fig. 2) . Furthermore, molecular knockdown of STIM1 abrogated Ca 2+ entry in ECs in response to both histamine and thrombin (Fig. 2) . We have reported similar results on the requirement of STIM1 for receptor-mediated Ca 2+ entry in human umbilical vein endothelial cells and human dermal microvascular endothelial cells upon stimulation with thrombin and vascular endothelial growth factor [1, 19] . Together, our results indicate that STIM1 in endothelial cells regulates nitric oxide and oxidative stress pathways and therefore the endothelium-dependent relaxation in resistance and conductance arteries.
We conclude that STIM1 plays an important role in the control of vascular tone with distinct roles in vascular smooth muscle and endothelial cells. In smooth muscle, STIM1 is required for vasoconstriction in response to phenylephrine likely through a specific effect on sympathetic activity. However, STIM1 in endothelial cells is required for Ca 2+ -dependent vasorelaxation through regulation of nitric oxide and oxidative stress pathways. While previously published studies have reported altered STIM1 expression in hypertension and type II diabetes, the distinction between endothelial and , and Stim1 EC−/+ smooth muscle cells has not been made under these conditions. Therefore, a careful assessment of these disease models with the mice described herein lacking STIM1 specifically in one of these two cell types is likely to help in the future specific targeting of this protein for the purpose of therapy of vascular diseases.
Material and methods
All experiments were performed according to the American Guidelines for the Ethical Care of Animals and were approved by both SUNY Albany and EVMS Animal Care and Use Committee. Stim1 knockout in smooth muscle cells male ) were generated in Dr. Mohamed Trebak laboratory using Stim1 flx/flx mice provided by Dr. Stefan Feske, NYU [15] . All mice were housed in groups of five mice, maintained at a temperature of 23°C with 12-h light/dark cycles and fed a solid standard diet (Na + content 0.4%) and water. The systolic blood pressure (SBP), body weight (BW), heart weight (HW)/tibia length ratio, and blood glucose levels were measured as previously described [14] .
Mice were anesthetized with isoflurane and then tissues (MRA and thoracic aorta) were immediately harvested, placed in PSS solution (composition in mM: NaCl 118; KCl 4.7; CaCl 2 2.5; KH 2 PO 4 1.2; MgSO 4 ×7H 2 O 1.2; NaHCO 3 25, and glucose 11, pH=7.4) and processed appropriately for further studies.
Vascular reactivity
Intact mesenteric resistance arteries (MRA) and intact thoracic aorta from control, Stim1
EC−/− and Stim1 EC−/+m ice were carefully cleaned from fat and connective tissue and then cut into rings (2 mm in length). Intact MRA and thoracic aorta were mounted in a small vessel dual chamber myograph for measurement of isometric tension at 37°C and oxygenation as previously described [20] . Cumulative concentration responses to phenylephrine (PE, 10 ).
Ca 2+ imaging
ECs were isolated and Fura2 imaging and data analysis were performed as described previously [1, 19] .
Western blot analysis
Western blot analyses were performed for STIM1 expression using STIM1 monoclonal antibody (BD Biosciences). Blots were stripped and then re-probed with β-actin to verify the equal loading among the samples.
NADPH oxidase activity NADPH oxidase activity in MRA and aorta from all groups was measured as previously described [13] . Additionally, we used laser-capture microdissection to study the NADPH oxidase activity in aortic EC and SMC independently.
Nitrates/nitrate and cGMP cGMP and nitrates nitrites levels were measured in aorta and MRA tissues in all groups of mice as described previously [6] .
Immunohistochemistry
Immunostaining was performed for STIM1, in paraffin sections of MRA and heart using specific antibodies, anti-STIM1 (1:200, BD Biosciences).
Statistical analysis
Results are expressed as mean±SEM. Concentration-response curves were analyzed using either GraphPad Prism 4.0 or Origin 8.0 software. One-way or two-way ANOVA was used to compare parameter when appropriate. Comparisons between groups were performed with t tests when the ANOVA test was statistically significant. Values of p<0.05 were considered significant. Differences between specified groups were analyzed using the Student's t test (two-tailed) for comparing two groups with p < 0.05 considered statistically significant.
